Skip to main content

Advertisement

SpringerLink
Log in

HLA-G Expression in Human Breast Cancer: Implications for Diagnosis and Prognosis, and Effect on Allocytotoxic Lymphocyte Response After Hormone Treatment In Vitro

  • Translational Research and Biomarkers
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Objective

The aim of this study is to investigate clinical implications of human leukocyte antigen-G (HLA-G) expression in breast cancer.

Methods

HLA-G expression in 235 primary breast cancer tissues was investigated using immunohistochemistry, and plasma soluble HLA-G (sHLA-G) was measured in 44 breast cancer patients using a specific HLA-G enzyme-linked immunosorbent assay (ELISA). Effects of estradiol/progesterone and their antagonists tamoxifen/RU486 on HLA-G expression in cultured breast cancer MCF-7 cells were determined by real-time polymerase chain reaction (PCR) and the ELISA. Alterations of HLA-G expression by the hormone treatments on subsequent allocytotoxic lymphocyte (allo-CTL) response were also examined.

Results

In the study, approximately 66% of neoplasm lesions were identified to have positive HLA-G expression. This expression was significantly correlated with tumor size, nodal status, and clinical disease stage (P = 0.0001, 0.012, and 0.0001, respectively). Patients with positive HLA-G expression had a lower survival rate than those with negative expression (P < 0.028). Plasma sHLA-G levels were significantly higher in breast cancer patients than in healthy controls (P < 0.001), with the area under the receiver-operating characteristic (ROC) curve being 0.95. HLA-G expression in breast cancer MCF-7 cells was enhanced by estradiol/progesterone but reduced by their antagonists. Cytotoxicity studies showed that allo-CTL response in MCF-7 cells was inhibited by prior treatment with estradiol/progesterone, but was amplified by their antagonists. The effects could be restored or further strengthened by the addition of anti-HLA-G antibodies.

Conclusion

Our findings suggest that HLA-G may have potential clinical implications in diagnosis, prognosis, and immunotherapy of patients with breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. LeMaoult J, Rouas-Freiss N, Carosella ED. Immuno-tolerogenic functions of HLA-G: relevance in transplantation and oncology. Autoimmun Rev. 2005;4:503–9.

    Article  CAS  PubMed  Google Scholar 

  2. Carosella ED, Moreau P, Lemaoult J, Rouas-Freiss N. HLA-G: from biology to clinical benefits. Trends Immunol. 2008;29:125–32.

    Article  CAS  PubMed  Google Scholar 

  3. Ye SR, Yang H, Li K, Dong DD, Lin XM, Yie SM. Human leukocyte antigen G expression: as a significant prognostic indicator for patients with colorectal cancer. Mod Pathol. 2007;20:375–83.

    Article  CAS  PubMed  Google Scholar 

  4. Yie SM, Yang H, Ye SR, Li K, Dong DD, Lin XM. Expression of HLA-G is associated with prognosis in esophageal squamous cell carcinoma. Am J Clin Pathol. 2007;128:1002–9.

    Article  PubMed  Google Scholar 

  5. Yie SM, Yang H, Ye SR, Li K, Dong DD, Lin XM. Expression of human leucocyte antigen G (HLA-G) is associated with prognosis in non-small cell lung cancer. Lung Cancer. 2007;58:267–74.

    Article  PubMed  Google Scholar 

  6. Yie SM, Yang H, Ye SR, Li K, Dong DD, Lin XM. Expression of human leukocyte antigen G (HLA-G) correlates with poor prognosis in gastric carcinoma. Ann Surg Oncol. 2007;14:2721–9.

    Article  PubMed  Google Scholar 

  7. Nückel H, Rebmann V, Dürig J, Dührsen U, Grosse-Wilde H. HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia. Blood. 2005;105:1694–8.

    Article  PubMed  Google Scholar 

  8. Lefebvre S, Antoine M, Uzan S, McMaster M, Dausset J, Carosella ED, et al. Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer. J Pathol. 2002;196:266–74.

    Article  CAS  PubMed  Google Scholar 

  9. Singer G, Rebmann V, Chen YC, Liu HT, Ali SZ, Reinsberg J, et al. HLA-G is a potential tumor marker in malignant ascites. Clin Cancer Res. 2003;9:4460–4.

    CAS  PubMed  Google Scholar 

  10. Kleinberg L, Flørenes VA, Skrede M, Dong HP, Nielsen SR, McMaster MT, et al. Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma. Virchows Arch. 2006;449:31–9.

    Article  CAS  PubMed  Google Scholar 

  11. Shih IeM. Application of human leukocyte antigen-G expression in the diagnosis of human cancer. Hum Immunol. 2007;68:272–6.

    Article  CAS  PubMed  Google Scholar 

  12. Benson JR, Pitsinis V. Update on clinical role of tamoxifen. Curr Opin Obstet Gynecol. 2003;15:13–23.

    Article  PubMed  Google Scholar 

  13. Klijn JG, Setyono-Han B, Foekens JA. Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer. Steroids. 2000;65:825–30.

    Article  CAS  PubMed  Google Scholar 

  14. Thomas M, Monet JD. Combined effects of RU486 and tamoxifen on the growth and cell cycle phases of the MCF-7 cell line. J Clin Endocrinol Metab. 1992;75:865–70.

    Article  CAS  PubMed  Google Scholar 

  15. Gaddy VT, Barrett JT, Delk JN, Kallab AM, Porter AG, Schoenlein PV. Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cells. Clin Cancer Res. 2004;10:5215–25.

    Article  CAS  PubMed  Google Scholar 

  16. Yie SM, Li LH, Li GM, Xiao R, Librach CL. Progesterone enhances HLA-G gene expression in JEG-3 choriocarcinoma cells and human cytotrophoblasts in vitro. Hum Reprod. 2006;21:46–51.

    Article  CAS  PubMed  Google Scholar 

  17. Sheshgiri R, Rao V, Tumiati LC, Xiao R, Prodger JL, Badiwala M, et al. Progesterone induces human leukocyte antigen-g expression in vascular endothelial and smooth muscle cells. Circulation. 2008;118(14 Suppl):S58–64.

    Article  CAS  PubMed  Google Scholar 

  18. Pangault C, Amiot L, Caulet-Maugendre S, Brasseur F, Burtin F, Guilloux V, et al. HLA-G protein expression is not induced during malignant transformation. Tissue Antigens. 1999;53:335–46.

    Article  CAS  PubMed  Google Scholar 

  19. Fleming I, Cooper J, Henson D, Hutter R, Kennedy B, Murphy G, et al. (editors) American Joint Committee on cancer staging manual. 5th ed. Philadephia: JB Lippincott;1997.

    Google Scholar 

  20. Yie S, Li L, Li Y, Librach C. HLA-G protein concentrations in maternal serum and placental tissue are decreased in preeclampsia. Am J Obstet Gynecol. 2004;191:525–9.

    Article  CAS  PubMed  Google Scholar 

  21. Kapasi K, Albert SE, Yie SM, Zavazava N, Librach CL. HLA-G has a concentration-dependent effect on the generation of an allo-CTL response. Immunology. 2000;101:191–200.

    Article  CAS  PubMed  Google Scholar 

  22. Alexander J, Watanabe T, Wu TT, Rashid A, Li S, Hamilton SR. Histopathological identification of colon cancer with microsatellite instability. Am J Pathol. 2001;158:527–35.

    CAS  PubMed  Google Scholar 

  23. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2–ΔΔCt method. Methods. 2001;25,402–8.

    Article  CAS  PubMed  Google Scholar 

  24. Ugurel S, Rebmann V, Ferrone S, Tilgen W, Grosse-Wilde H, Reinhold U. Soluble human leukocyte antigen–G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy. Cancer. 2001;92:369–76.

    Article  CAS  PubMed  Google Scholar 

  25. Leleu X, Le Friec G, Facon T, Amiot L, Fauchet R, Hannache B, et al. Total soluble HLA class I and soluble HLA-G in multiple myeloma and monoclonal gammopathy of undetermined significance. Clin Cancer Res. 2005;11:7297–303.

    Article  CAS  PubMed  Google Scholar 

  26. Gros F, Sebti Y, de Guibert S, Branger B, Bernard M, Fauchet R, et al. Soluble HLA-G molecules increase during acute leukemia, especially in subtypes affecting monocytic and lymphoid lineages. Neoplasia. 2006;8:223–30.

    Article  CAS  PubMed  Google Scholar 

  27. Sebti Y, Le Maux A, Gros F, De Guibert S, Pangault C, Rouas-Freiss N, et al. Expression of functional soluble human leucocyte antigen-G molecules in lymphoproliferative disorders. Br J Haematol. 2007;138: 202–12.

    Article  CAS  PubMed  Google Scholar 

  28. Morandi F, Levreri I, Bocca P, Galleni B, Raffaghello L, Ferrone S, et al. Human neuroblastoma cells trigger an immunosuppressive program in monocytes by stimulating soluble HLA-G release. Cancer Res. 2007;67:6433–41.

    Article  CAS  PubMed  Google Scholar 

  29. MacGregor JI, Jordan VC. Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev. 1998;50:151–96.

    CAS  PubMed  Google Scholar 

  30. Schild-Hay LJ, Leil TA, Divi RL, Olivero OA, Weston A, Poirier MC. Tamoxifen induces expression of immune response-related genes in cultured normal human mammary epithelial cells. Cancer Res. 2009;69:1150–5.

    Article  CAS  PubMed  Google Scholar 

  31. Regelson W. RU486: how abortion politics have impacted on a potentially useful drug of broad medical application. Perspect Biol Med. 1992;35:330–8.

    CAS  PubMed  Google Scholar 

  32. Slavin S. Allogeneic cell-mediated immunotherapy at the stage of minimal residual disease following high-dose chemotherapy supported by autologous stem cell transplantation. Acta Haematol. 2005;114:214–20.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Core Laboratory, Sichuan Academy of Medical Sciences, Chengdu, Sichuan, People’s Republic of China

    Xu He PhD, Shang-mian Yie PhD, Mei Cao PhD & Jie Chen BM

  2. Department of Pathology, Sichuan Provincial People’s Hospital, Chengdu, Sichuan, People’s Republic of China

    Dan-dan Dong MD, Hong Yang MD & Ke Li BM

  3. Chengdu Bioengineering Institute for Cancer Research, Chengdu, Sichuan, People’s Republic of China

    Shang-mian Yie PhD, Shang-rong Ye MD & Ji Liu MSc

Authors
  1. Xu He PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dan-dan Dong MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shang-mian Yie PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hong Yang MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mei Cao PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shang-rong Ye MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ke Li BM
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ji Liu MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jie Chen BM
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shang-mian Yie PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

He, X., Dong, Dd., Yie, Sm. et al. HLA-G Expression in Human Breast Cancer: Implications for Diagnosis and Prognosis, and Effect on Allocytotoxic Lymphocyte Response After Hormone Treatment In Vitro. Ann Surg Oncol 17, 1459–1469 (2010). https://doi.org/10.1245/s10434-009-0891-9

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-009-0891-9

Keywords

Search

Navigation